Holen Sie sich die Stockscreener-App
1.20
1.64%
-0.02
Handel nachbörslich:
1.18
-0.02
-1.67%
Schlusskurs vom Vortag:
$1.22
Offen:
$1.23
24-Stunden-Volumen:
271.70K
Relative Volume:
0.25
Marktkapitalisierung:
$16.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.51M
KGV:
-0.9091
EPS:
-1.32
Netto-Cashflow:
$-8.02M
1W Leistung:
+0.84%
1M Leistung:
+29.03%
6M Leistung:
+55.82%
1J Leistung:
+35.90%
1-Tages-Spanne:
$1.17
$1.23
1-Wochen-Bereich:
$1.11
$1.23
52-Wochen-Spanne:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Firmenname
Hoth Therapeutics Inc
Sektor
Branche
Telefon
(646)756-2997
Adresse
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Vergleichen Sie HOTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.20 | 16.51M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-10-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Aktie (HOTH) Neueste Nachrichten
Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa
Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com
Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener
Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus
Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan
Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX
Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan
Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener
Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com
Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan
Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug - Investing.com India
Hoth Therapeutics plans expanded access program for cancer skin toxicity drug By Investing.com - Investing.com South Africa
Hoth Therapeutics, Inc. Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities - MarketScreener
Hoth Therapeutics Launches Expanded Access Initiative For HT-001 - MarketScreener
HOTH Seeks Expanded Access for HT-001 to Address Skin Toxicities | HOTH Stock News - GuruFocus
Hoth Expands Access to Cancer Skin Toxicity Treatment HT-001 in Phase 2a Success | HOTH Stock News - Stock Titan
Hoth Therapeutics advances with HT-001 oncology skin care treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics advances with HT-001 oncology skin care treatment - Investing.com Australia
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities - PR Newswire
First-Ever Treatment for EGFR Cancer Therapy Skin Toxicities: Experts Review Game-Changing Clinical Data - Stock Titan
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Large Increase in Short Interest - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Stock Rating Upgraded by Wall Street Zen - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Shares Up 0.7% – What’s Next? - Defense World
Hoth Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Hoth Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HOTH THERAPEUTICS Earnings Results: $HOTH Reports Quarterly Earnings - Nasdaq
Hoth Therapeutics reports promising HT-KIT preclinical results By Investing.com - Investing.com Canada
Hoth Therapeutics, Inc. SEC 10-Q Report - TradingView
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers - PR Newswire
Hoth Therapeutics reports promising HT-KIT preclinical results - Investing.com Australia
Hoth Therapeutics (HOTH) Expected to Announce Earnings on Tuesday - Defense World
Geode Capital Management LLC Purchases 13,038 Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) - Defense World
Hoth Therapeutics confirms patent application fee payment By Investing.com - Investing.com Nigeria
Hoth Therapeutics confirms patent application fee payment - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models - Curetoday
Quarterly Snapshot: Quick and Current Ratios for Hoth Therapeutics Inc (HOTH) - DWinneX
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene - Investing.com Canada
Hoth secures Japan patent for RNA cancer therapy targeting KIT gene By Investing.com - Investing.com South Africa
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT GeneExpands Global IP in Precision Oncology Platform - PR Newswire
Hoth Therapeutics (HOTH) Reports Promising Phase 2a Results for Pruritus Treatment | HOTH Stock News - GuruFocus
Hoth Therapeutics reports progress in pruritus treatment trial By Investing.com - Investing.com South Africa
Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial - marketscreener.com
Finanzdaten der Hoth Therapeutics Inc-Aktie (HOTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):